WILMINGTON, Del., May 8, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.:
- Do you own shares of Synageva BioPharma Corp. (NASDAQ GS: GEVA)?
- Did you purchase any of your shares prior to May 6, 2015?
- Do you think the proposed buyout value is too low?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Synageva BioPharma Corp. ("Synageva" or the "Company") (NASDAQ GS: GEVA) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Alexion Pharmaceuticals, Inc. ("Alexion") (NASDAQ GS: ALXN), in a transaction valued at approximately $8.4 billion.
Click here to learn more: http://rigrodskylong.com/investigations/synageva-biopharma-corp-geva.
Under the terms of the agreement, shareholders of Synageva will receive $115 in cash and 0.6581 shares of Alexion for each share of Synageva they own. Based on Alexion's closing price on May 5, 2015, Synageva shareholders would have received compensation valued at approximately $225.92 per share.
The investigation concerns whether Synageva's board of directors failed to adequately shop the Company and obtain the best possible value for Synageva's shareholders before entering into an agreement with Alexion.
If you own the common stock of Synageva and purchased your shares before May 5, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://rigrodskylong.com/investigations/synageva-biopharma-corp-geva.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synageva-biopharma-corp-shareholder-alert-rigrodsky--long-pa-announces-investigation-of-buyout-300080555.html
SOURCE Rigrodsky & Long, P.A.